Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun;9(6):e003138.
doi: 10.1136/jitc-2021-003138.

Author response to Colle et al

Giovanni Fucà  1 , Francesca Corti  1 , Filippo Pietrantonio  2
Affiliations
Comment

Author response to Colle et al

Giovanni Fucà et al. J Immunother Cancer. 2021 Jun.

Abstract

The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, with early assessments being associated with higher incidence. Such dynamics should be considered when interpreting the efficacy of treatment.

Keywords: gastrointestinal neoplasms; immunotherapy; tumor biomarkers.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

  • Letter to the Editor from Colle et al.
    Colle R, Andre T, Menu Y. Colle R, et al. J Immunother Cancer. 2021 Jun;9(6):e002997. doi: 10.1136/jitc-2021-002997. J Immunother Cancer. 2021. PMID: 34162716 Free PMC article.

References

    1. Colle R, Andre T, Menu Y. Letter to the editor from Colle et al. J Immunother Cancer 2021. 10.1136/jitc-2021-002997 - DOI - PMC - PubMed
    1. Fucà G, Corti F, Ambrosini M, et al. . Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer 2021;9. 10.1136/jitc-2021-002501 - DOI - PMC - PubMed
    1. Colle R, Radzik A, Cohen R, et al. . Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Eur J Cancer 2021;144:9–16. 10.1016/j.ejca.2020.11.009 - DOI - PubMed
    1. Seymour L, Bogaerts J, Perrone A, et al. . iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143–52. 10.1016/S1470-2045(17)30074-8 - DOI - PMC - PubMed

LinkOut - more resources